IRMD

IRADIMED CORPORATION Healthcare - Medical Devices Investor Relations →

NO
71.6% ABOVE
↓ Approaching Was 75.2% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $53.72
14-Week RSI 36
Rel. Volume (14w) This week's trading vs. the 14-week average 1.3x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.27

IRADIMED CORPORATION (IRMD) closed at $92.20 as of 2026-06-19, trading 71.6% above its 200-week moving average of $53.72. The stock is currently moving closer to the line, down from 75.2% last week. The 14-week RSI sits at 36, indicating neutral momentum.

Trading volume is running at 1.3x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.27 ratio) is neutral — neither side is clearly dominating.

Over the past 574 weeks of data, IRMD has crossed below its 200-week moving average 9 times. On average, these episodes lasted 10 weeks. Historically, investors who bought IRMD at the start of these episodes saw an average one-year return of +11.0%.

With a market cap of $1179 million, IRMD is a small-cap stock. The company generates a free cash flow yield of 1.3%. Return on equity stands at 25.0%, indicating strong profitability. The stock trades at 12.0x book value.

Over the past 11.1 years, a hypothetical investment of $100 in IRMD would have grown to $459, compared to $437 for the S&P 500. That represents an annualized return of 14.7% vs 14.2% for the index — confirming IRMD as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.

Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: IRMD vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After IRMD Crosses Below the Line?

Across 9 historical episodes, buying IRMD when it crossed below its 200-week moving average produced an average return of +8.6% after 12 months (median +0.0%), compared to +19.8% for the S&P 500 over the same periods. 44% of those episodes were profitable after one year. After 24 months, the average return was +61.9% vs +46.6% for the index.

Each line shows $100 invested at the moment IRMD crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Bean Score Experimental

The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices IRMD would reach each dislocation threshold.

Current Bean Score +0.39σ
Current FCF Yield 2.02%
Baseline Yield 1.95%
Historical σ 0.10pp

Dislocation Price Levels

Prices where IRMD's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-07-30.

LevelσPriceSignal
Deep Value+2σ$85.89Unusually cheap — potential buy zone
Value+1σ$90.21Cheap vs. own history
Fair Value+0σ$94.99Historical mean behavior
Expensive-1σ$100.30Expensive vs. own history
Deep Expensive-2σ$106.25Unusually expensive — potential trim zone

Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end

Data depth: 2 quarterly baselines, 22 price observations — Limited history (4+ quarters preferred for reliability)

Signal Accuracy Collecting Data

The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"

11 / 13 weeks minimum

Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.

Dislocation Scores Experimental

Each score measures deviation from IRMD's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

Yield Dislocation -0.76σ Dividend yield vs own 10-yr norm
Drawdown Score -1.18σ Distance from line vs own history
Sector-Relative -1.71σ Vs sector median this week
Buyback Acceleration +0.1pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity N/A TTM buys / market cap, percentile of buyers
FCF Yield vs History -0.5pp Vs own recent annual mean
Earnings Quality Stable Accrual gap trend (-2.8pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Advertisement

Historical Touches

IRMD has crossed below its 200-week MA 9 times with an average 1-year return of +11.0% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Feb 2016Feb 2016217.1%-39.3%+594.3%
Apr 2016May 2016617.7%-43.4%+598.6%
Aug 2016Aug 201612.6%-43.2%+483.8%
Aug 2016Dec 20176850.4%-39.6%+485.2%
Jan 2018Apr 20181213.5%+73.2%+579.8%
Jul 2019Jul 201910.5%+31.0%+460.9%
Mar 2020Mar 2020111.8%+45.8%+529.9%
Oct 2022Oct 202210.6%+44.3%+257.3%
Dec 2022Dec 202210.4%+70.6%+254.6%
Average10+11.0%

Frequently Asked Questions

Is IRMD below its 200-week moving average?

No. IRADIMED CORPORATION (IRMD) is currently 71.6% above its 200-week moving average of $53.72. It would need to fall to $53.72 to cross below the line.

What is IRMD's 200-week moving average price?

IRADIMED CORPORATION's 200-week moving average is $53.72 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when IRMD drops below its 200-week moving average?

IRMD has crossed below its 200-week moving average 9 times in our data. On average, buying at that moment produced a one-year return of +11.0%. These dips have historically been decent entry points. These episodes lasted 10 weeks on average.

Is IRMD a good value right now?

Here's what our data says about IRMD as of 2026-06-19: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 36. Free cash flow yield is 1.3%. Return on equity is 25.0%. Price-to-book is 12.0x. This is not a buy or sell recommendation — always do your own research.

How does IRMD compare to the S&P 500?

Over the past 11.1 years, $100 invested in IRMD would have grown to $459, compared to $437 for the S&P 500. That's 14.7% annualized vs 14.2% for the index. IRMD has outperformed the broader market over this period.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-06-19